SAN

80.34

-0.25%↓

UCB

269.7

+0.37%↑

SHL.DE

37.31

-1.43%↓

ARGX

674

+0.78%↑

VIE

34.81

+0.81%↑

SAN

80.34

-0.25%↓

UCB

269.7

+0.37%↑

SHL.DE

37.31

-1.43%↓

ARGX

674

+0.78%↑

VIE

34.81

+0.81%↑

SAN

80.34

-0.25%↓

UCB

269.7

+0.37%↑

SHL.DE

37.31

-1.43%↓

ARGX

674

+0.78%↑

VIE

34.81

+0.81%↑

SAN

80.34

-0.25%↓

UCB

269.7

+0.37%↑

SHL.DE

37.31

-1.43%↓

ARGX

674

+0.78%↑

VIE

34.81

+0.81%↑

SAN

80.34

-0.25%↓

UCB

269.7

+0.37%↑

SHL.DE

37.31

-1.43%↓

ARGX

674

+0.78%↑

VIE

34.81

+0.81%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

82.4 -0.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

81.9

Max

83.05

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

34.873

66.418

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+7.3% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

233M

4.2B

Ouverture précédente

82.88

Clôture précédente

82.4

Sentiment de l'Actualité

By Acuity

50%

50%

168 / 349 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 avr. 2026, 20:44 UTC

Résultats

Costco Reports 11% Growth in March Sales

8 avr. 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 avr. 2026, 23:36 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 avr. 2026, 22:56 UTC

Market Talk

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 avr. 2026, 22:45 UTC

Market Talk

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 avr. 2026, 22:17 UTC

Market Talk

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 avr. 2026, 21:52 UTC

Principaux Événements d'Actualité

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 avr. 2026, 21:24 UTC

Résultats

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 avr. 2026, 21:01 UTC

Principaux Événements d'Actualité

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 avr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

8 avr. 2026, 20:43 UTC

Acquisitions, Fusions, Rachats

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 avr. 2026, 20:43 UTC

Acquisitions, Fusions, Rachats

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 avr. 2026, 20:43 UTC

Acquisitions, Fusions, Rachats

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 avr. 2026, 20:42 UTC

Acquisitions, Fusions, Rachats

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 avr. 2026, 20:42 UTC

Acquisitions, Fusions, Rachats

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 avr. 2026, 20:42 UTC

Acquisitions, Fusions, Rachats

Oracle Responds to TRC Cap Mini-Tender Offer

8 avr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 avr. 2026, 19:44 UTC

Résultats

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 avr. 2026, 19:16 UTC

Market Talk

Hogs Follow Cutout Prices Lower -- Market Talk

8 avr. 2026, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

8 avr. 2026, 19:02 UTC

Market Talk

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 avr. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 avr. 2026, 18:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8 avr. 2026, 18:51 UTC

Market Talk

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 avr. 2026, 18:14 UTC

Principaux Événements d'Actualité

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 avr. 2026, 18:05 UTC

Principaux Événements d'Actualité

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

7.3% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  7.3%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

168 / 349Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat